Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer.

@article{Liu2019ImprovedEA,
  title={Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer.},
  author={X. Liu and Jinhong Jiang and Ryan Chan and Ying Ji and Jianqin Lu and Y. Liao and Michael Okene and Joshua Lin and Paulina Lin and C. Chang and X. Wang and Ivanna Tang and Emily Zheng and Waveley Qiu and Z. Wainberg and A. Nel and Huan Meng},
  journal={ACS nano},
  year={2019},
  volume={13 1},
  pages={
          38-53
        }
}
Irinotecan is a key chemotherapeutic agent for the treatment of colorectal (CRC) and pancreatic (PDAC) cancer. Because of a high incidence of bone marrow and gastrointestinal (GI) toxicity, Onivyde (a liposome) was introduced to provide encapsulated irinotecan (Ir) delivery in PDAC patients. While there is an ongoing clinical trial (NCT02551991) to investigate the use of Onivyde as a first-line option to replace irinotecan in FOLFIRINOX, the liposomal formulation is currently prescribed as a… Expand

Paper Mentions

Interventional Clinical Trial
This is an open-label, phase 2 comparative study to assess the safety, tolerability, and preliminary efficacy of nal-IRI in combination with other anticancer therapies in patients… Expand
ConditionsPancreatic Cancer
InterventionDrug
Irinotecan: 25 years of cancer treatment.
  • C. Bailly
  • Medicine, Biology
  • Pharmacological research
  • 2019
Orally Administrable Therapeutic Nanoparticles for the Treatment of Colorectal Cancer
Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses
...
1
2
3
...

References

SHOWING 1-10 OF 84 REFERENCES
...
1
2
3
4
5
...